Use of kinase inhibitors to manage tuberculosis and other infectious diseases
AssigneeEmory University
InventorDaniel Kalman
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.
Claims19
A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with another antibiotic selected from ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, rifapentine, amikacin, capreomycin, cycloserine, ethionamide, levofloxacin, moxifloxacin, para-aminosalicylic acid, streptomycin, or combinations thereof, to a human subject in need thereof.
A pharmaceutical product comprising a combination of imatinib and an antiviral agent.
A method of treating or preventing tuberculosis comprising administering imatinib to a human subject in need thereof diagnosed with HIV.
A method of preventing reactivation of a latent tuberculosis infection comprising administering imatinib in an amount of 50 to 400 mg per day to a human subject in need thereof, wherein administration prevents reactivation of a latent tuberculosis infection.
A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day to a human subject in need thereof, wherein the subject is resistant to treatment of tuberculosis with rifampicin.
A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with bedaquiline to a human subject in need thereof.
A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with delamanid to a human subject in need thereof.
Dependencies are inferred from the claim text.